Conventional Assessment Tools and Therapies for a Neurological Disease? The Example of Parkinson's Disease

被引:31
|
作者
Asakawa, Tetsuya [1 ,2 ]
Sugiyama, Kenji [1 ]
Nozaki, Takao [1 ]
Sameshima, Tetsuro [1 ]
Kobayashi, Susumu [1 ]
Wang, Liang [3 ]
Hong, Zhen [3 ]
Chen, Shujiao [2 ]
Li, Candong [2 ]
Namba, Hiroki [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka, Japan
[2] Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, Fuzhou, Fujian, Peoples R China
[3] Fudan Univ, Dept Neurol, Huashan Hosp, Shanghai, Peoples R China
基金
日本学术振兴会;
关键词
neurological diseases; Parkinson's disease; motor fluctuations; behavioral assessments; wearable device; augmented reality (AR)/virtual reality (VR); robot assistant system; rehabilitation; DEEP BRAIN-STIMULATION; BODY AREA NETWORK; VIRTUAL-REALITY; BEHAVIORAL ASSESSMENTS; MOTOR FLUCTUATIONS; WEARABLE SYSTEM; ROBOT; GAIT; LEVODOPA; MOVEMENT;
D O I
10.2176/nmc.ra.2018-0045
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dramatic breakthroughs in the treatment and assessment of neurological diseases are lacking. We believe that conventional methods have several limitations. Computerized technologies, including virtual reality, augmented reality, and robot assistant systems, are advancing at a rapid pace. In this study, we used Parkinson's disease (PD) as an example to elucidate how the latest computerized technologies can improve the diagnosis and treatment of neurological diseases. Dopaminergic medication and deep brain stimulation remain the most effective interventions for treating PD. Subjective scales, such as the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr stage, are still the most widely used assessments. Wearable sensors, virtual reality, augmented reality, and robot assistant systems are increasingly being used for evaluation of patients with PD. The use of such computerized technologies can result in safe, objective, real-time behavioral assessments. Our experiences and understanding of PD have led us to believe that such technologies can provide real-time assessment, which will revolutionize the traditional assessment and treatment of PD. New technologies are desired that can revolutionize PD treatment and facilitate real-time adjustment of treatment based on motor fluctuations, such as telediagnosis systems and "smart treatment systems." The use of these technologies will substantially improve both the assessment and the treatment of neurological diseases before next-generation treatments, such as stem cell and genetic therapy, and next-generation assessments, can be clinically practiced, although the current level of artificial intelligence cannot replace the role of clinicians.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 50 条
  • [1] Population genetic approaches to neurological disease: Parkinson's disease as an example
    Gandhi, S
    Abou-Sleiman, PM
    Healy, DG
    Weale, M
    Gilks, W
    Ahmadi, K
    Goldstein, DB
    Wood, NW
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2005, 360 (1460) : 1573 - 1578
  • [2] An Insight into the Conventional and Ayurvedic Therapies for the Treatment of Parkinson's Disease
    Dey, Tulika
    Zahra, Kulsoom
    Byadgi, Parmeswarappa Shivappa
    Singh, Anup
    Mishra, Surendra Pratap
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (01) : KE1 - KE5
  • [3] The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies
    Goetz, Christopher G.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2011, 1 (01):
  • [4] The promise of telemedicine for chronic neurological disorders: the example of Parkinson's disease
    Schneider, Ruth B.
    Biglan, Kevin M.
    LANCET NEUROLOGY, 2017, 16 (07): : 541 - 551
  • [5] Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease
    Katta, Madhumitha
    Mathew, Blessy Aksa
    Chaturvedi, Pragya
    Ludhiadch, Abhilash
    Munshi, Anjana
    NEUROLOGICAL SCIENCES, 2023, 44 (01) : 19 - 36
  • [6] Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease
    Madhumitha Katta
    Blessy Aksa Mathew
    Pragya Chaturvedi
    Abhilash Ludhiadch
    Anjana Munshi
    Neurological Sciences, 2023, 44 : 19 - 36
  • [7] Evaluation of Cognitive Assessment Tools in Parkinson's Disease
    Cao, L.
    Huang, Y.
    MOVEMENT DISORDERS, 2023, 38 : S148 - S148
  • [8] Nonmotor Effects of Conventional and Transdermal Dopaminergic Therapies in Parkinson's Disease
    Kim, Ryul
    Jeon, Beomseok
    NONMOTOR PARKINSON'S: THE HIDDEN FACE - MANAGEMENT AND THE HIDDEN FACE OF RELATED DISORDERS, 2017, 134 : 989 - 1018
  • [9] RNA biomarkers of Parkinson's disease: developing tools for novel therapies
    Hennecke, Gerrit
    Scherzer, Clemens R.
    BIOMARKERS IN MEDICINE, 2008, 2 (01) : 41 - 53
  • [10] Therapies in Parkinson's disease
    Jankovic, Joseph
    Poewe, Werner
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) : 433 - 447